Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%

REPLIGEN CORP

Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).
Deal expected to close Q4 2026; boards unanimously approved; subject to BLFS stockholder approval and HSR clearance.
Expected to be accretive: at least $0.05 adjusted EPS in year one, at least $0.25 in year two.
Repligen preliminary Q2 revenue growth ~12% (13% organic); BioLife preliminary Q2 revenue growth ~21% YoY.

item 1.01 item 2.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.